新生血管性年龄相关性黄斑变性中的桥拱形视网膜下液:演变与结局
单中心回顾性研究纳入431例慢性脉络膜新生血管膜患者共623眼,其中21例患者24眼(4%)出现桥拱形视网膜下液。桥拱形视网膜下液出现时视力下降-20.57±31.13个早期治疗糖尿病视网膜病变研究字母(P=0.033),末次随访时进一步下降-7.136±13.73个字母(P=0.011)。作者认为该征象是纤维化扩大的标志,尽管治疗反应良好但视力结局差。
要点
- 桥拱形视网膜下液见于慢性2型脉络膜新生血管膜眼,发生率4%(24/623眼)。
- 出现桥拱形视网膜下液时视力下降-20.57±31.13个字母(P=0.033),末次随访再降-7.136±13.73个字母(P=0.011)。
- 作者认为视网膜色素上皮破损与撕裂及非积极抗血管内皮生长因子注射方案可能参与其发病。
核心结论
- 桥拱形视网膜下液是慢性2型脉络膜新生血管膜眼少见的征象,是纤维化扩大的标志,尽管治疗反应良好但导致视力结局差。
- 作者认为视网膜色素上皮破损与撕裂及非积极抗血管内皮生长因子注射治疗方案可能参与其发病。
研究设计与样本
- 单中心回顾性研究,纳入伴有桥拱形视网膜下液和脉络膜新生血管膜的患者。
- 共识别431例患者623眼慢性脉络膜新生血管膜,其中21例患者24眼(4%)显示桥拱形视网膜下液。
- 患者平均年龄69.19±12.0岁。
主要发现
- 桥拱形视网膜下液出现前79%病例为1型脉络膜新生血管膜。
- 出现桥拱形视网膜下液的平均时间为21.9±30.63个月,出现前平均玻璃体内抗血管内皮生长因子注射次数为6.5±7.09次。
- 桥拱形视网膜下液出现时平均早期治疗糖尿病视网膜病变研究字母视力为53.93±32.19,视力下降-20.57±31.13个字母(P=0.033),并见纤维化2型脉络膜新生血管膜(n=18,75%)。
- 8眼(33%)见视网膜色素上皮撕裂。
- 末次随访时,桥拱形视网膜下液出现后视力进一步下降-7.136±13.73个早期治疗糖尿病视网膜病变研究字母(P=0.011),出现后平均注射次数为4.76±3.76次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study factors leading to bridge arch-shaped subretinal fluid (SRF) on optical coherence tomography in wet age-related macular degeneration and evaluate its anatomical and functional outcomes. METHODS: In this single-center, retrospective study, patients with bridge arch-shaped SRF and choroidal neovascular membrane (CNVM) were included. RESULTS: Overall, 623 eyes in 431 patients with chronic CNVM were identified, and 24 eyes (4%) in 21 patients showed bridge arch-shaped SRF. Mean age of patients was 69.19 ± 12.0 years. Type-1 CNVM was noted in 79% cases before development of bridge arch-shaped SRF. Mean early treatment diabetic retinopathy letters visual acuity was 53.93 ± 32.19. Time interval to develop bridge arch-shaped SRF was 21.9 ± 30.63 months. Mean number of intravitreal anti-vascular endothelial growth factor injections given before developing bridge arch-shaped SRF was 6.5 ± 7.09. During the development of bridge arch-shaped SRF, visual acuity reduced by -20.57 ± 31.13 letters (P = 0.033) and fibrotic Type-2 CNVM (n = 18, 75%) was noted. Retinal pigment epithelium tear was noted in 8 eyes (33%). At the final visit, further reduction in visual acuity of -7.136 ± 13.73 early treatment diabetic retinopathy letters (P = 0.011) after developing bridge arch-shaped SRF was seen. Mean number of injections given after developing bridge arch-shaped SRF was 4.76 ± 3.76. CONCLUSION: Bridge arch-shaped SRF is an uncommon finding seen in eyes with Type-2 chronic CNVMs. Presence of retinal pigment epithelium breach and tear and nonaggressive treatment regimen with intravitreal anti-vascular endothelial growth factor injections could be responsible for its pathogenesis. It is a marker of fibrotic enlargement, leading to poor visual outcomes despite showing favorable therapeutic response.
引用
- Venkatesh R, Mangla R, Mishra P, et al. BRIDGE ARCH-SHAPED SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Evolution and Outcomes. Retina. 2022. PMID: 35152246. doi:10.1097/IAE.0000000000003436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。